feed
view company updates
tools
perform investment research
network
join events & discussions
advisory
about us
Redeye Capital
Promore Pharma: Mixed data (continued)
Research Note
2020-12-02
08:35
Redeye lowers its valuation of Promore Pharma (base case at SEK 6) following mixed study data from its phase IIb trial.
FT
Fredrik Thor
Sign up for free to continue
Sign up with Email
Sign in with Google
Already a member?
Sign in
Disclosures and disclaimers
Premium Plan required to unlock
Unlock companies to access
more high quality research.
View Plans